Document is current
Any future updates will be listed below
-
Authors
Hurst, Christopher https://orcid.org/0000-0002-7239-6599
McDonald, Claire https://orcid.org/0000-0002-7592-9952
Cooper, Rachel https://orcid.org/0000-0003-3370-5720
Sayer, Avan A. https://orcid.org/0000-0003-1283-6457
Witham, Miles D. https://orcid.org/0000-0002-1967-0990
-
Funding
Funding for this research was provided by:
NIHR Newcastle Biomedical Research Centre (203309)
- License Information
-
More Information
Article History
Received: 28 June 2025
Revised: 15 September 2025
Accepted: 18 September 2025
First Online: 7 October 2025
Declarations
:
: AAS and MDW are named collaborators on a research project with Regeneron Pharmaceuticals. AAS is involved in a collaborative research project with Pfizer and MDW has received consultancy fees for sarcopenia trial design from Rejuvenate Biomed.
: Following UK Health Research Authority ( ) guidance, the project was not classified as research and so did not require research ethics approval.
: Not applicable.
